[en] Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects. This is because reported frequencies vary widely across studies, partly because of diverse definitions of toxic effects. Using the Delphi method, 15 international childhood acute lymphoblastic leukaemia study groups assessed acute lymphoblastic leukaemia protocols to address toxic effects that were to be considered by the Ponte di Legno working group. 14 acute toxic effects (hypersensitivity to asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated pancreatitis, arterial hypertension, posterior reversible encephalopathy syndrome, seizures, depressed level of consciousness, methotrexate-related stroke-like syndrome, peripheral neuropathy, high-dose methotrexate-related nephrotoxicity, sinusoidal obstructive syndrome, thromboembolism, and Pneumocystis jirovecii pneumonia) that are serious but too rare to be addressed comprehensively within any single group, or are deemed to need consensus definitions for reliable incidence comparisons, were selected for assessment. Our results showed that none of the protocols addressed all 14 toxic effects, that no two protocols shared identical definitions of all toxic effects, and that no toxic effect definition was shared by all protocols. Using the Delphi method over three face-to-face plenary meetings, consensus definitions were obtained for all 14 toxic effects. In the overall assessment of outcome of acute lymphoblastic leukaemia treatment, these expert opinion-based definitions will allow reliable comparisons of frequencies and severities of acute toxic effects across treatment protocols, and facilitate international research on cause, guidelines for treatment adaptation, preventive strategies, and development of consensus algorithms for reporting on acute lymphoblastic leukaemia treatment.
Disciplines :
Pediatrics Oncology Hematology
Author, co-author :
Schmiegelow, Kjeld
Attarbaschi, Andishe
Barzilai, Shlomit
Escherich, Gabriele
Frandsen, Thomas Leth
Halsey, Christina
Hough, Rachael
Jeha, Sima
Kato, Motohiro
Liang, Der-Cherng
Mikkelsen, Torben Stamm
Moricke, Anja
Niinimaki, Riitta
Piette, Caroline ; Université de Liège > Département des sciences cliniques > Pédiatrie
2 Oeffinger, KC, Mertens, AC, Sklar, CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355 (2006), 1572–1582.
3 Essig, S, Li, QZ, Chen, Y, et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 15 (2014), 841–851.
5 US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf, May 28, 2009 (accessed Nov 4, 2015).
6 Alexander, S, Pole, JD, Gibson, P, et al. Development of a reliable and valid system for classifying treatment-related mortality in children with cancer. Lancet Oncol 16 (2015), e604–e610.
7 Zafar, SY, Currow, DC, Cherny, N, Strasser, F, Fowler, R, Abernethy, AP, Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol 13 (2012), e77–e82.
8 Powell, C, The Delphi technique: myths and realities. J Adv Nurs 41 (2003), 376–382.
9 Tong, WH, Pieters, R, Kaspers, GJL, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 123 (2014), 2026–2033.
10 Ko, RH, Jones, TL, Radvinsky, D, et al. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: a children's oncology group report. Cancer 121 (2015), 4205–4211.
11 Niinimaki, T, Harila-Saari, A, Niinimaki, R, The diagnosis and classification of osteonecrosis in patients with childhood leukemia. Pediatr Blood Cancer 62 (2015), 198–203.
12 Mattano, LA Jr, Devidas, M, Nachman, JB, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol 13 (2012), 906–915.
13 Niinimaki, T, Niinimaki, J, Halonen, J, Hanninen, P, Harila-Saari, A, Niinimaki, R, The classification of osteonecrosis in patients with cancer: validation of a new radiological classification system. Clin Radiol 70 (2015), 1439–1444.
15 Banks, PA, Bollen, TL, Dervenis, C, et al., Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus. Gut 62 (2013), 102–111.
16 Kamdem, LK, Hamilton, L, Cheng, C, et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics 18 (2008), 507–514.
17 US Department of Health and Human Services. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. http://www.nhlbi.nih.gov/files/docs/resources/heart/hbp_ped.pdf (accessed Nov 4, 2015).
18 de Laat, P, Te Winkel, ML, Devos, AS, et al. Posterior reversible encephalopathy syndrome in childhood cancer. Ann Oncol 22 (2011), 472–478.
20 Rubnitz, JE, Relling, MV, Harrison, PL, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 12 (1998), 1176–1181.
21 Bond, J, Hough, R, Moppett, J, Vora, A, Mitchell, C, Goulden, N, ‘Stroke-like syndrome’ caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial. Leukemia 27 (2013), 954–956.
22 Diouf, B, Crews, KR, Lew, G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313 (2015), 815–823.
23 Lavoie Smith, EM, Li, L, Hutchinson, RJ, et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 36 (2013), E49–E60.
24 Widemann, BC, Schwartz, S, Jayaprakash, N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy 34 (2014), 427–439.
25 Escherich, G, Richards, S, Stork, LC, Vora, AJ, Childhood Acute Lymphoblastic Leukaemia Collaborative G. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia 25 (2011), 953–959.
26 Grace, RF, Dahlberg, SE, Neuberg, D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 152 (2011), 452–459.
27 Levinsen, M, Shabaneh, D, Bohnstedt, C, et al. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. Eur J Haematol 88 (2012), 78–86.
28 Lund, LW, Winther, JF, Dalton, SO, et al. Hospital contact for mental disorders in survivors of childhood cancer and their siblings in Denmark: a population-based cohort study. Lancet Oncol 14 (2013), 971–980.
29 Licht, SD, Winther, JF, Gudmundsdottir, T, et al. Hospital contacts for endocrine disorders in adult life after childhood cancer in Scandinavia (ALiCCS): a population-based cohort study. Lancet 383 (2014), 1981–1989.
30 Frandsen, TL, Heyman, M, Abrahamsson, J, et al. Complying with the European Clinical Trials directive while surviving the administrative pressure—an alternative approach to toxicity registration in a cancer trial. Eur J Cancer 50 (2014), 251–259.
31 Miller, TP, Li, Y, Kavcic, M, et al. Accuracy of adverse event ascertainment in clinical trials for pediatric acute myeloid leukemia. J Clin Oncol 34 (2016), 1537–1543.
